Molecular Profiling Project

Launched by NATIONAL CANCER CENTRE, SINGAPORE · Jul 18, 2019

Keywords

ClinConnect Summary

The Molecular Profiling Project is a clinical trial focused on understanding the different genetic types of non-small cell lung cancer in patients. The researchers aim to analyze tumor samples to identify specific genetic changes that could affect how the cancer behaves and how it can be treated. This study is currently recruiting participants aged 21 and older who have enough tumor tissue available for testing and can meet certain health criteria, such as having a good level of organ function.

If you or someone you know is interested in participating, they should have a life expectancy of at least 12 weeks and be willing to undergo routine blood tests to ensure they are eligible. Participants can expect to provide a tumor sample and to be a part of research that may help improve future treatments for lung cancer. Remember, if someone does not meet all the standard criteria, there may still be a chance to discuss enrollment with the study team on a case-by-case basis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The availability of sufficient archival tumor tissue specimen (15 slides of 4 microns per section)
• • Age ≥ 21 years
• • WHO performance status ≤ 2
• • Life expectancy of ≥ 12 weeks
• * Patients should have adequate organ function for potential consideration into clinical trials (routine blood tests are valid within 14 days before enrollment):
• • Adequate bone marrow function as shown by: ANC ≥ 1.0 x 10\^9/L, Platelets ≥ 75 x 10\^9/L, Hb ≥ 7.5 g/dL
• • Alanine aminotransferase (ALT) and aspirate aminotransferase (AST) normal range (or ≤3.0 x ULN if liver metastases are present)
• • Willing to provide signed informed consent
• • Patients whom do not fulfill the above criteria may be discussed on a case-by-case basis with the study team, for potential enrolment
• Exclusion Criteria:
• • - No more than 3 lines of cytotoxic chemotherapy at the time of enrolment